CL2014000401A1 - Proteina de union a antigeno especifica para el heterodimero alfa4beta7; y composicion que la comprende (div.sol.n°2306-11). - Google Patents

Proteina de union a antigeno especifica para el heterodimero alfa4beta7; y composicion que la comprende (div.sol.n°2306-11).

Info

Publication number
CL2014000401A1
CL2014000401A1 CL2014000401A CL2014000401A CL2014000401A1 CL 2014000401 A1 CL2014000401 A1 CL 2014000401A1 CL 2014000401 A CL2014000401 A CL 2014000401A CL 2014000401 A CL2014000401 A CL 2014000401A CL 2014000401 A1 CL2014000401 A1 CL 2014000401A1
Authority
CL
Chile
Prior art keywords
heterodimer
div
sol
composition
antigen binding
Prior art date
Application number
CL2014000401A
Other languages
English (en)
Inventor
Taruna Arora
Hailing Hsu
Ian Foltz
Frederick W Jacobsen
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42224952&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014000401(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2014000401A1 publication Critical patent/CL2014000401A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
CL2014000401A 2009-03-20 2014-02-18 Proteina de union a antigeno especifica para el heterodimero alfa4beta7; y composicion que la comprende (div.sol.n°2306-11). CL2014000401A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16215409P 2009-03-20 2009-03-20
US30682910P 2010-02-22 2010-02-22

Publications (1)

Publication Number Publication Date
CL2014000401A1 true CL2014000401A1 (es) 2014-08-29

Family

ID=42224952

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2011002306A CL2011002306A1 (es) 2009-03-20 2011-09-16 Anticuerpo o un fragmento de union a antigeno del mismo que se une especificamente a la integrina heterodimero alfa4beta7; y composicion que lo comprende.
CL2014000400A CL2014000400A1 (es) 2009-03-20 2014-02-18 Proteina de union al antigeno especifica para el heterodimero alfa4beta7; y composicion que la comprende (div.sol.n°2306-11).
CL2014000401A CL2014000401A1 (es) 2009-03-20 2014-02-18 Proteina de union a antigeno especifica para el heterodimero alfa4beta7; y composicion que la comprende (div.sol.n°2306-11).

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CL2011002306A CL2011002306A1 (es) 2009-03-20 2011-09-16 Anticuerpo o un fragmento de union a antigeno del mismo que se une especificamente a la integrina heterodimero alfa4beta7; y composicion que lo comprende.
CL2014000400A CL2014000400A1 (es) 2009-03-20 2014-02-18 Proteina de union al antigeno especifica para el heterodimero alfa4beta7; y composicion que la comprende (div.sol.n°2306-11).

Country Status (27)

Country Link
US (6) US8444981B2 (es)
EP (1) EP2408816B1 (es)
JP (3) JP5498566B2 (es)
KR (2) KR101346530B1 (es)
CN (2) CN103382222B (es)
AR (1) AR075882A1 (es)
AU (1) AU2010226814B2 (es)
CA (2) CA2851737C (es)
CL (3) CL2011002306A1 (es)
CO (1) CO6501170A2 (es)
CR (1) CR20110544A (es)
EA (1) EA034783B1 (es)
ES (1) ES2751946T3 (es)
HK (1) HK1168116A1 (es)
IL (4) IL214868A (es)
JO (1) JO3615B1 (es)
MA (1) MA33213B1 (es)
MX (4) MX357213B (es)
MY (2) MY184957A (es)
NZ (1) NZ595464A (es)
PE (2) PE20120497A1 (es)
SG (3) SG10201801337WA (es)
TN (1) TN2011000433A1 (es)
TW (2) TWI466681B (es)
UY (1) UY32501A (es)
WO (1) WO2010107752A2 (es)
ZA (1) ZA201107279B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
MX367097B (es) 2011-05-02 2019-08-05 Millennium Pharm Inc FORMULACION PARA ANTICUERPO ANTI-A4ß7.
US9914779B2 (en) 2011-11-23 2018-03-13 Amgen Inc. Administration of alpha4beta7 hetero-dimer-specific antibody
CN104662044B (zh) 2012-08-24 2018-10-30 加利福尼亚大学董事会 用于治疗ror1癌症并抑制转移的抗体和疫苗
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
EP3712166A1 (en) 2013-09-05 2020-09-23 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
WO2015129858A1 (ja) * 2014-02-28 2015-09-03 アステラス製薬株式会社 新規ヒトｔｌｒ２及びヒトｔｌｒ４に結合する二重特異的抗体
WO2015175861A1 (en) 2014-05-16 2015-11-19 Amgen Inc. Assay for detecting th1 and th2 cell populations
MX2017002380A (es) 2014-08-22 2017-09-15 Sorrento Therapeutics Inc Proteinas de union de antigeno que se unen a cxcr3.
WO2016057424A1 (en) 2014-10-06 2016-04-14 Chemocentryx, Inc. Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alha4beta7 integrin blocking antibodies
US20170327584A1 (en) 2014-11-26 2017-11-16 Millennium Pharmaceuticals, Inc. Vedolizumab for the Treatment of Fistulizing Crohn's Disease
MA41636A (fr) 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
EP3328994A4 (en) 2015-07-31 2019-04-17 Memorial Sloan-Kettering Cancer Center CD56 TARGETING ANTIGEN BINDING PROTEINS AND USES THEREOF
EP3336184A4 (en) 2015-08-11 2019-01-23 Osaka University ANTIBODY
AU2017234009A1 (en) 2016-03-14 2018-09-27 Millennium Pharmaceuticals, Inc. Method of preventing graft versus host disease
BR112018068625A2 (pt) 2016-03-14 2019-07-30 Millennium Pharm Inc métodos de tratamento ou prevenção de doença de enxerto contra hospedeiro
AU2017237543B2 (en) * 2016-03-23 2020-02-06 Institut Pasteur Korea Antibody that binds to envelope glycoprotein of severe fever with thrombocytopenia syndrome virus, and use for same
US11760803B2 (en) 2016-03-24 2023-09-19 Takeda Pharmaceutical Company Limited Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
TW201735949A (zh) 2016-03-24 2017-10-16 千禧製藥公司 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
MA44723A (fr) 2016-04-18 2019-02-27 Celldex Therapeutics Inc Anticorps agonistes se liant au cd40 humain et leurs utilisations
WO2017218434A1 (en) 2016-06-12 2017-12-21 Millennium Pharmaceuticals, Inc. Method of treating inflammatory bowel disease
AU2017289270B2 (en) 2016-06-27 2023-05-04 The Regents Of The University Of California Cancer treatment combinations
AU2018235928B2 (en) 2017-03-14 2023-09-21 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
BR112019022268A2 (pt) 2017-04-28 2020-05-19 Millennium Pharm Inc método para o tratamento de distúrbios pediátricos
MA52186A (fr) 2018-03-26 2021-02-17 Amgen Inc Glycoformes afucosylées totales d'anticorps produits en culture cellulaire
WO2021062372A1 (en) 2019-09-26 2021-04-01 Amgen Inc. Methods of producing antibody compositions
HUE062777T2 (hu) 2020-02-26 2023-12-28 Vir Biotechnology Inc SARS-CoV-2 elleni antitestek
EP4162257A1 (en) 2020-06-04 2023-04-12 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
EP4229080A1 (en) 2020-10-15 2023-08-23 Amgen Inc. Relative unpaired glycans in antibody production methods
AU2022232943A1 (en) * 2021-03-12 2023-09-28 Icahn School Of Medicine At Mount Sinai Neutralizing monoclonal antibodies to bk virus
EP4352094A1 (en) 2021-06-07 2024-04-17 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
WO2023059607A1 (en) 2021-10-05 2023-04-13 Amgen Inc. Fc-gamma receptor ii binding and glycan content
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US714785A (en) 1901-07-03 1902-12-02 Benjamin M Davis Disinfecting apparatus.
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
AU8727291A (en) 1990-10-29 1992-06-11 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
AU678787B2 (en) 1992-10-23 1997-06-12 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
CN1211123C (zh) 1994-01-25 2005-07-20 雅典娜神经科学公司 抗白细胞粘附分子vla－4的人源化抗体
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
AU7676300A (en) * 1999-10-12 2001-04-23 Cambridge Antibody Technology Limited Human anti-adipocyte monoclonal antibodies and their use
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
US20010046496A1 (en) 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
WO2002078779A1 (fr) * 2001-03-27 2002-10-10 Zeon Corporation Fil-guide medical
US20040221327A1 (en) 2001-03-27 2004-11-04 Gershwin M. Eric Antibodies against autoantigens of primary billary cirrhosis and methods of making and using them
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
RS20050834A (en) 2002-08-19 2007-12-31 Abgenix Inc., Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
SV2006001990A (es) * 2004-01-09 2006-01-30 Pfizer Anticuerpos contra madcam
JP2008515774A (ja) 2004-08-03 2008-05-15 ダイアックス コーポレイション ｈＫ１結合タンパク質
WO2006104978A2 (en) 2005-03-25 2006-10-05 Curagen Corporation Antibodies against the tenascin major antigens
US7480268B2 (en) 2005-07-28 2009-01-20 Symbol Technologies, Inc. System and method for multiprotocol wireless communication
JP2009515552A (ja) 2005-11-17 2009-04-16 ミレニアム・ファーマシューティカルズ・インコーポレイテッド α４β７インテグリン反応性ヒト化免疫グロブリン
US7910703B2 (en) * 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use

Also Published As

Publication number Publication date
KR101346530B1 (ko) 2013-12-31
AU2010226814A1 (en) 2011-09-29
IL214868A (en) 2015-08-31
US8444981B2 (en) 2013-05-21
IL239965A (en) 2016-10-31
TN2011000433A1 (en) 2013-03-27
JP5498566B2 (ja) 2014-05-21
AR075882A1 (es) 2011-05-04
MX357211B (es) 2018-06-29
MY184957A (en) 2021-04-30
JP2014140372A (ja) 2014-08-07
IL239965A0 (en) 2015-08-31
NZ595464A (en) 2013-08-30
AU2010226814B2 (en) 2013-05-16
KR20130067314A (ko) 2013-06-21
CO6501170A2 (es) 2012-08-15
CA2851737A1 (en) 2010-09-23
JP5775615B2 (ja) 2015-09-09
CL2014000400A1 (es) 2014-08-29
US20120177662A1 (en) 2012-07-12
IL214868A0 (en) 2011-11-30
MX2014013424A (es) 2015-07-29
US20130302354A1 (en) 2013-11-14
US9499620B2 (en) 2016-11-22
CN103382222A (zh) 2013-11-06
CL2011002306A1 (es) 2012-01-13
CR20110544A (es) 2011-12-07
CN103382222B (zh) 2016-12-28
JP2012520679A (ja) 2012-09-10
EA034783B1 (ru) 2020-03-20
SG10201801337WA (en) 2018-03-28
TW201036626A (en) 2010-10-16
US8871490B2 (en) 2014-10-28
MY162752A (en) 2017-07-14
MX357213B (es) 2018-06-29
JP5980384B2 (ja) 2016-08-31
TWI466681B (zh) 2015-01-01
CA2851737C (en) 2019-01-08
IL232008A (en) 2015-11-30
US20100254975A1 (en) 2010-10-07
TW201418281A (zh) 2014-05-16
EP2408816B1 (en) 2019-09-04
PE20120497A1 (es) 2012-05-14
EP2408816A2 (en) 2012-01-25
MA33213B1 (fr) 2012-04-02
JP2015214563A (ja) 2015-12-03
MX2011009897A (es) 2011-12-08
KR20110128948A (ko) 2011-11-30
PE20160553A1 (es) 2016-05-18
WO2010107752A3 (en) 2011-01-20
WO2010107752A2 (en) 2010-09-23
US20170275365A1 (en) 2017-09-28
UY32501A (es) 2010-04-30
SG174344A1 (en) 2011-11-28
CA2754113A1 (en) 2010-09-23
EA201171148A1 (ru) 2012-04-30
US8454962B2 (en) 2013-06-04
ZA201107279B (en) 2012-12-27
IL232009A0 (en) 2014-05-28
US8454961B2 (en) 2013-06-04
ES2751946T3 (es) 2020-04-02
IL232008A0 (en) 2014-05-28
US20120183561A1 (en) 2012-07-19
CA2754113C (en) 2014-08-05
US20150086563A1 (en) 2015-03-26
IL232009A (en) 2015-11-30
MX338969B (es) 2016-05-06
CN102388068A (zh) 2012-03-21
SG10201400798VA (en) 2014-07-30
JO3615B1 (ar) 2020-08-27
CN102388068B (zh) 2015-05-20
KR101391472B1 (ko) 2014-05-07
TWI477511B (zh) 2015-03-21
HK1168116A1 (en) 2012-12-21

Similar Documents

Publication Publication Date Title
CL2014000401A1 (es) Proteina de union a antigeno especifica para el heterodimero alfa4beta7; y composicion que la comprende (div.sol.n°2306-11).
CY2019004I1 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
HK1254184A1 (zh) 對抗rgm a蛋白質之單株抗體及其用途
IL214996A (en) An isolated antibody linked to the bcma polypeptide, a pharmaceutical preparation containing it and its uses
DK2234600T3 (da) Antistofformulering
BRPI0921469A2 (pt) proteínas de ligação que inibem a interação com o receptor de vegf-a
ZA201002422B (en) Modified antibody constant region
BRPI0918947A2 (pt) proteína de fusão de anticorpo
DK2066695T3 (da) Anti-myostatin-antistoffer
BRPI0923231A2 (pt) anticorpo anti-cmet.
CR10705A (es) Anticuerpos para linfotoxina-alfa
BRPI0807991A2 (pt) Anticorpos anti-il-23r elaborados.
DK2171053T3 (da) Natriuretiske polypeptider
BRPI0911922A2 (pt) sistema de entrada interativo e conjunto de iluminação para o mesmo
BRPI0907237A2 (pt) Anticorpo anti-cldn6
FI20070853A0 (fi) Glykaania sitovat monoklonaaliset vasta-aineet
BRPI0923199A2 (pt) métodos e composições para detecção de anticorpos com fixação de complemento.
BRPI0814111A2 (pt) Anticorpo monoclonal citotóxico anticâncer
BRPI0817427A2 (pt) Anticorpo anti-bst2
FR2903733B1 (fr) Turbomoteur pour aeronef.
DK2150276T3 (da) Antistoffer, som binder til et intracellulært prl-1- eller prl-3-polypeptid
BRPI0814127A2 (pt) Polipeptídeos imunegênicos e anticorpos monoclonais
FR2919810B1 (fr) Objet volant.
NL2002173A1 (nl) Synthetic Aviation Fuel.
BRPI0814116A2 (pt) Anticorpo monoclonal citotóxico anticâncer